XML 52 R43.htm IDEA: XBRL DOCUMENT v3.25.1
License and Collaboration Agreements - Additional Information (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended
Feb. 28, 2025
Jan. 31, 2022
Mar. 31, 2025
Feb. 14, 2025
Biogen License Agreement        
License And Collaboration Agreement [Line Items]        
Initial transaction price     $ 243.4  
Non-refundable upfront payment     165.0  
Estimated variable consideration related to cost reimbursements for global development activities     78.4  
Upfront consideration related to performance obligations     14.0  
Acadia Pharmaceuticals Inc.        
License And Collaboration Agreement [Line Items]        
Upfront Payment received   $ 60.0    
Potential milestone payments receivable   $ 907.5    
Remaining upfront consideration     $ 14.4  
Biogen International GmbH | Licensing Agreements        
License And Collaboration Agreement [Line Items]        
Upfront Payment received $ 165.0      
Development milestone payments receivable 50.0      
Commercial milestone payments receivable $ 335.0      
Percentage of development costs       70.00%
Percentage of remaining development costs       30.00%